Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production

The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis. Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contribut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biochim Biophys Acta Mol Cell Biol Lipids
Main Authors: Fruhwürth, Stefanie, Krieger, Sigurd, Winter, Katharina, Rosner, Margit, Mikula, Mario, Weichhart, Thomas, Bittman, Robert, Hengstschläger, Markus, Stangl, Herbert
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487575/
https://ncbi.nlm.nih.gov/pubmed/24713582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbalip.2014.03.014
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados